Results for "Teva Pharmaceutical Industries"

Aurinia Pharmaceuticals has reached a settlement in its patent litigation concerning Lupkynis with Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries saw its shares climb after reporting revenue that surpassed expectations and growth in innovative drugs, which helped to mitigate an overall earnings miss.

Teva Pharmaceutical Industries is experiencing a boom in its biosimilar business, leading to speculation among investors about the potential for its rebounding stock.

Financial analyses are being conducted to determine if Kratos Defense & Security Solutions, Inc. and Teva Pharmaceutical Industries Limited are currently good stocks for investors to purchase. These reports offer insights into their respective market positions.

Teva Pharmaceutical Industries and Constellium have both reported their first-quarter earnings, surpassing analyst estimates for their financial performance. Both companies also provided updates on their respective business outlooks for the year.

Billionaire investor Stan Druckenmiller has reportedly reduced his holdings in Teva Pharmaceutical Industries Limited (TEVA).

Blackstone (BX) has committed $400 million in partnership with Teva Pharmaceutical Industries to advance the clinical development of Duvakitug.

Humana has agreed not to mention Teva Pharmaceutical Industries' ties to Israel during a US drug trial, a development in the ongoing legal proceedings.

Teva Pharmaceutical Industries Limited (TEVA) stock is being considered undervalued after a recent pullback and an update regarding its vitiligo program.

Teva Pharmaceutical Industries' stock has reached its highest level in almost ten years, with market analysts suggesting potential for further growth.

Teva Pharmaceutical Industries held its Q1 earnings call, presenting key financial highlights and updates on its operations.

Teva Pharmaceutical Industries reported a Q1 earnings beat but subsequently lowered its 2026 financial outlook. The revised forecast is attributed to the company's acquisition of Emalex Biosciences.

Teva Pharmaceutical Industries has received approval for its biosimilar version of Amgen's osteoporosis drug, Prolia.

Goldman Sachs anticipates double-digit earnings growth for Teva Pharmaceutical Industries through 2026, while Edison International posts strong 2025 results and sets 2026–2027 EPS targets. Needham is bullish on Neurocrine Biosciences' pipeline, expecting growth from Crenessity and Ingrezza by 2026.

Teva Pharmaceutical Industries Limited is evaluating how new results for its drug Austedo could enhance its neurology portfolio.

Teva Pharmaceutical Industries announced its first-quarter earnings, showing a surge in AUSTEDO sales. The company also revealed plans for a $700 million buyout of Emalex.

Teva Pharmaceutical Industries has announced a new acquisition deal valued at $700 million. This strategic move is expected to expand the company's portfolio and market presence.

Investor David Einhorn's firm has reportedly trimmed its holdings in Teva Pharmaceutical Industries Limited and Kyndryl Holdings Inc. This move suggests a strategic reduction in exposure to these two companies.

An article evaluates whether PepsiCo, Inc. (PEP) presents a favorable investment opportunity for stock buyers.